ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 191 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $944,219 | -5.1% | 45,308 | +9.1% | 0.00% | 0.0% |
| Q2 2023 | $994,811 | +107.7% | 41,537 | +63.2% | 0.00% | +100.0% |
| Q1 2023 | $478,856 | +12.7% | 25,444 | +54.6% | 0.00% | 0.0% |
| Q1 2021 | $425,000 | -80.6% | 16,458 | -59.9% | 0.00% | -77.8% |
| Q4 2020 | $2,194,000 | +15.5% | 41,038 | -10.9% | 0.01% | 0.0% |
| Q3 2020 | $1,900,000 | -49.5% | 46,063 | -40.7% | 0.01% | -50.0% |
| Q2 2020 | $3,766,000 | +36.4% | 77,704 | +18.9% | 0.02% | +5.9% |
| Q1 2020 | $2,760,000 | +43.2% | 65,330 | +45.1% | 0.02% | +70.0% |
| Q4 2019 | $1,927,000 | +29.2% | 45,033 | +8.6% | 0.01% | +25.0% |
| Q3 2019 | $1,492,000 | +255.2% | 41,459 | +163.7% | 0.01% | +300.0% |
| Q2 2019 | $420,000 | -52.6% | 15,720 | -52.4% | 0.00% | -60.0% |
| Q1 2019 | $887,000 | -87.1% | 33,045 | -92.7% | 0.01% | -86.8% |
| Q2 2018 | $6,877,000 | +1553.1% | 450,345 | +3425.2% | 0.04% | +850.0% |
| Q1 2015 | $416,000 | – | 12,775 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| March Altus Capital Management LP | 82,723 | $2,685,000 | 20.75% |
| HWG Holdings LP | 289,380 | $9,393,000 | 8.72% |
| Baker Brothers Advisors | 24,516,738 | $795,813,000 | 8.34% |
| HARVEY CAPITAL MANAGEMENT INC | 352,200 | $11,432,000 | 5.73% |
| Belmont Global Advisors, Inc. | 150,000 | $4,869,000 | 4.67% |
| Palo Alto Investors LP | 1,437,730 | $46,669,000 | 3.52% |
| Avoro Capital Advisors LLC | 329,500 | $10,696,000 | 2.38% |
| GARRISON BRADFORD & ASSOCIATES INC | 70,100 | $2,275,000 | 2.23% |
| WEATHERBIE CAPITAL, LLC | 401,642 | $13,037,000 | 1.85% |
| ACUTA CAPITAL PARTNERS, LLC | 85,999 | $2,792,000 | 1.34% |